Background And Objectives: A postauthorization safety study was performed between 2009 and 2012 to describe the use of Clottafact in acquired fibrinogen deficiency in real-life medical practice in France.
Materials And Methods: One hundred and fifty patients were planned for 28 days of prospective follow-up after infusion. The analysis of this observational study was descriptive and performed according to the type of treatment (curative or preventive) and the origin of the bleed.
Purpose: Data for ANCA-associated vasculitis (AAV) patients requiring intensive care are scarce.
Methods: We included 97 consecutive patients with acute AAV manifestations (new onset or relapsing disease), admitted to 18 intensive care units (ICUs) over a 10-year period (2002-2012). A group of 95 consecutive AAV patients with new onset or relapsing disease, admitted to two nephrology departments with acute vasculitis manifestations, constituted the control group.
Evidence-based medicine criticism. Evidence-based medicine is now considered as the rule in the practice of clinical medicine. It covers however a lot of issues and limitations, leading to numerous and severe pitfalls.
View Article and Find Full Text PDF